Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brigitte Sola

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Cell Cycle (Georgetown, Tex.)|June 25, 2016
HIF-1α and rapamycin act as gerosuppressant in multiple myeloma cells upon genotoxic stressClémence Coudre, Julien Alani, William Ritchie, et al.
Annals of the New York Academy of Sciences|March 23, 2004
The selective estrogen receptor modulator 4-hydroxy tamoxifen induces G1 arrest and apoptosis of multiple myeloma cell linesJuliette Gauduchon, Fabrice Gouilleux, Sébastien Maillard, et al.
International Journal of Cancer|January 10, 2008
Pure antiestrogen-induced G1-arrest in myeloma cells results from the reduced kinase activity of cyclin D3/CDK6 complexes whereas apoptosis is mediated by endoplasmic reticulum-dependent caspasesJuliette Gauduchon, Amélie Seguin, Véronique Marsaud, et al.
Recent Patents on Inflammation & Allergy Drug Discovery|December 17, 2008
Anti-tumor necrosis factor-alpha (TNF-alpha) treatment strategies in Crohn's diseaseJean-Marie Reimund, Julia Ratajczyk, Brigitte Sola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2005
4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family membersJuliette Gauduchon, Fabrice Gouilleux, Sébastien Maillard, et al.
Oncotarget|June 11, 2016
Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cellsSophie Bustany, Jérôme Bourgeais, Guergana Tchakarska, et al.
Plos One|May 5, 2017
[18F]Fludarabine-PET in a murine model of multiple myelomaNarinée Hovhannisyan, Martine Dhilly, Martin Fidalgo, et al.
Advances in Experimental Medicine and Biology|April 11, 2020
Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell LymphomaMaria Gonzalez-Santamarta, Grégoire Quinet, Diana Reyes-Garau, et al.
Plos One|September 26, 2014
Deazaneplanocin a is a promising drug to kill multiple myeloma cells in their nicheJérémie Gaudichon, Francesco Milano, Julie Cahu, et al.
Oncotarget|August 28, 2013
Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolismBrigitte Sola, Marc Poirot, Philippe de Medina, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Cell Cycle (Georgetown, Tex.)|June 25, 2016
HIF-1α and rapamycin act as gerosuppressant in multiple myeloma cells upon genotoxic stressClémence Coudre, Julien Alani, William Ritchie, et al.
Annals of the New York Academy of Sciences|March 23, 2004
The selective estrogen receptor modulator 4-hydroxy tamoxifen induces G1 arrest and apoptosis of multiple myeloma cell linesJuliette Gauduchon, Fabrice Gouilleux, Sébastien Maillard, et al.
International Journal of Cancer|January 10, 2008
Pure antiestrogen-induced G1-arrest in myeloma cells results from the reduced kinase activity of cyclin D3/CDK6 complexes whereas apoptosis is mediated by endoplasmic reticulum-dependent caspasesJuliette Gauduchon, Amélie Seguin, Véronique Marsaud, et al.
Recent Patents on Inflammation & Allergy Drug Discovery|December 17, 2008
Anti-tumor necrosis factor-alpha (TNF-alpha) treatment strategies in Crohn's diseaseJean-Marie Reimund, Julia Ratajczyk, Brigitte Sola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2005
4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family membersJuliette Gauduchon, Fabrice Gouilleux, Sébastien Maillard, et al.
Oncotarget|June 11, 2016
Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cellsSophie Bustany, Jérôme Bourgeais, Guergana Tchakarska, et al.
Plos One|May 5, 2017
[18F]Fludarabine-PET in a murine model of multiple myelomaNarinée Hovhannisyan, Martine Dhilly, Martin Fidalgo, et al.
Advances in Experimental Medicine and Biology|April 11, 2020
Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell LymphomaMaria Gonzalez-Santamarta, Grégoire Quinet, Diana Reyes-Garau, et al.
Plos One|September 26, 2014
Deazaneplanocin a is a promising drug to kill multiple myeloma cells in their nicheJérémie Gaudichon, Francesco Milano, Julie Cahu, et al.
Oncotarget|August 28, 2013
Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolismBrigitte Sola, Marc Poirot, Philippe de Medina, et al.
Pageof 5